Literature DB >> 20224595

Factor V Leiden mutation in Arabs in Kuwait by real-time PCR: different values for different Arabs.

Ali A Dashti1, Mehrez M Jadaon, Hend L Lewis.   

Abstract

Factor V Leiden (FVL) mutation (G1691A) is a risk factor for development of venous thromboembolic disorders. FVL was found mostly in Caucasians (1-15%) but was almost absent in non-Caucasians. Studies on Arab patients and populations revealed very inconsistent results. This study reports FVL in Arabs living in Kuwait with a focus on the nationality of the Arab subjects studied. Whole-blood samples were collected from 400 healthy Arabs who were 268 Kuwaitis (67%), 50 Syrians (12.5%), 34 Jordanians (8.5%), 8 Palestinians (2%) and 40 Egyptians (10%). DNA extraction was carried out for these blood samples and real-time PCR was performed to detect the presence of FVL. Generally, 36 cases (9%) had the mutation (33 were heterozygous and 3 were homozygous), with an allelic frequency of 0.049. The prevalence of FVL differed in different Arabic cases: Kuwaitis 4.5%, Egyptians 15%, Syrians 16%, Jordanians 23.5% and Palestinians 25%. The allelic frequency was 0.022 in the Kuwaitis and 0.088-0.132 in non-Kuwaitis. The three homozygous cases were from Syria, Jordan and Egypt. In conclusion, the prevalence of FVL in Arabs living in Kuwait is as high as in Caucasians. There is a difference in prevalence among Arabs themselves, being relatively lower in Kuwaitis than in non-Kuwaitis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20224595     DOI: 10.1038/jhg.2010.11

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  6 in total

1.  Factor V Leiden, prothrombin 20210G>A, MTHFR 677C>T and 1298A>C, and homocysteinemia in Tunisian blood donors.

Authors:  Samira Hadhri; Mohamed Ben Rejab; Hajer Guedria; Lamia Ifa; Noureddine Chatti; Hadef Skouri
Journal:  J Clin Lab Anal       Date:  2012-05       Impact factor: 2.352

2.  Impact of Prothrombotic Risk Factors in a Cohort of Egyptian Hemophilia A Patients.

Authors:  Mona Salah El-Din Hamdy; Aml Soliman Nasr; Manal Mohamed Makhlouf; Zainab Ali El-Saadany; Magy Samir; Dalia Saber Morgan
Journal:  Mol Diagn Ther       Date:  2016-04       Impact factor: 4.074

3.  Race differences in the prevalence of the factor V Leiden mutation in Kuwaiti nationals.

Authors:  Ali A Dashti; Mehrez M Jadaon
Journal:  Mol Biol Rep       Date:  2010-11-21       Impact factor: 2.316

4.  Prevalence of positive factor V Leiden and prothrombin mutations in samples tested for thrombophilia in Saudi Arabia.

Authors:  Fatimah Madkhaly; Abdulaziz Alshaikh; Hala Aba Alkhail; Randa Alnounou; Tarek Owaidah
Journal:  Am J Blood Res       Date:  2021-06-15

5.  Epidemiology of activated protein C resistance and factor v leiden mutation in the mediterranean region.

Authors:  Mehrez M Jadaon
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-09-08       Impact factor: 2.576

6.  The prevalence of Factor V Leiden (Arg506Gln) mutation in King Khalid University Hospital patients, 2017-2019.

Authors:  Maram Al-Otaiby; Rahaf Althnayan; Alanoud Binmethem; Reema Bader AlEnezy; Munira Abdulrahman Alhadlg; Arjuwana Alaqeel; Sara H AlQahtani; Noman Ghufran; Abdulaziz A Alotaibi; Nada Alayed; Imran Ali Khan
Journal:  Nagoya J Med Sci       Date:  2021-08       Impact factor: 1.131

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.